Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice (original) (raw)

• Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.
  Article PubMed Google Scholar
• Hortobagyi GN . Treatment of breast cancer. N Engl J Med. 1998;339:974–984.
  Article CAS PubMed Google Scholar
• Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854–856.
  CAS PubMed Google Scholar
• Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373–376.
  Article CAS PubMed Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879–885.
  Article CAS PubMed Google Scholar
• Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000;60:6359–6366.
  CAS PubMed Google Scholar
• Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798–806.
  CAS PubMed Google Scholar
• Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy. 2000;7:867–874.
  Article CAS PubMed Google Scholar
• Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 2001;7:781–787.
  Article CAS PubMed Google Scholar
• Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821–825.
  Article CAS PubMed Google Scholar
• Balachandran S, Barber GN . Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life. 2000;50:135–138.
  Article CAS PubMed Google Scholar
• Balachandran S, Barber GN . Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell. 2004;5:51–65.
  Article CAS PubMed Google Scholar
• Rose JK, Whitt MA . Rhabdoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001: 1221–1242.
  Google Scholar
• Marcus PI, Rodriguez LL, Sekellick MJ . Interferon induction as a quasispecies marker of vesicular stomatitis virus populations. J Virol. 1998;72:542–549.
  CAS PubMed PubMed Central Google Scholar
• Ferran MC, Lucas-Lenard JM . The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J Virol. 1997;71:371–377.
  CAS PubMed PubMed Central Google Scholar
• Ahmed M, McKenzie MO, Puckett S, et al. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol. 2003;77:4646–4657.
  Article CAS PubMed PubMed Central Google Scholar
• Petersen JM, Her LS, Varvel V, et al. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol. 2000;20:8590–8601.
  Article CAS PubMed PubMed Central Google Scholar
• von Kobbe C, van Deursen JM, Rodrigues JP, et al. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell. 2000;6:1243–1252.
  Article CAS PubMed Google Scholar
• Francoeur AM, Poliquin L, Stanners CP . The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology. 1987;160:236–245.
  Article CAS PubMed Google Scholar
• Desforges M, Charron J, Berard S, et al. Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Res. 2001;76:87–102.
  Article CAS PubMed Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263–275.
  Article CAS PubMed Google Scholar
• Obuchi M, Fernandez M, Barber GN . Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol. 2003;77:8843–8856.
  Article CAS PubMed PubMed Central Google Scholar
• Shinozaki K, Ebert O, Kournioti C, et al. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther. 2004;9:368–376.
  Article CAS PubMed Google Scholar
• Lawson ND, Stillman EA, Whitt MA, et al. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA. 1995;92:4477–4481.
  Article CAS PubMed PubMed Central Google Scholar
• Whelan SP, Ball LA, Barr JN, et al. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA. 1995;92:8388–8392.
  Article CAS PubMed PubMed Central Google Scholar
• Ebert O, Shinozaki K, Huang TG, et al. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 2003;63:3605–3611.
  CAS PubMed Google Scholar
• Morecki S, Yacovlev E, Diab A, et al. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 1998;58:3891–3895.
  CAS PubMed Google Scholar
• Pulaski BA, Ostrand-Rosenberg S . Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998;58:1486–1493.
  CAS PubMed Google Scholar
• Huang TG, Ebert O, Shinozaki K, et al. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther. 2003;8:434–440.
  Article CAS PubMed Google Scholar
• Charan S, Zinkernagel RM . Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus. J Immunol. 1986;136:3057–3061.
  CAS PubMed Google Scholar
• Kundig TM, Schorle H, Bachmann MF, et al. Immune responses in interleukin-2-deficient mice. Science. 1993;262:1059–1061.
  Article CAS PubMed Google Scholar
• Fernandez M, Porosnicu M, Markovic D, et al. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol. 2002;76:895–904.
  Article CAS PubMed PubMed Central Google Scholar
• Porosnicu M, Mian A, Barber GN . The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res. 2003;63: 8366–8376.
  CAS PubMed Google Scholar
• Bateman A, Bullough F, Murphy S, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 2000;60:1492–1497.
  CAS PubMed Google Scholar
• Ebert O, Shinozaki K, Kournioti C, et al. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 2004;64:3265–3270.
  Article CAS PubMed Google Scholar